On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6.
Guidance for 2018
BioMarin Pharmaceutical anticipates that its net revenues in fiscal 2018 will be $1.47 billion–$1.53 billion.
It anticipates R&D (research and development) expenses of $645 million–$685 million and SG&A (selling, general, and administrative) expenses of $645 million–$685 million. It expects its cost of sales in fiscal 2018 to be 20%–21% of its net revenues.
BioMarin Pharmaceutical also estimates that its GAAP net income will be -$115 million to -$165 million and non-GAAP net income of $100 million to $140 million.
Its revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index ETF (FBT). BioMarin Pharmaceutical makes up ~3.15% of FBT’s total portfolio holdings.
Of the 23 analysts tracking BioMarin Pharmaceutical (BMRN) in August, nine of them have recommended a “strong buy,” while ten have recommended a “buy.” Four analysts have recommended a “hold.”
On August 31, BioMarin Pharmaceutical had a consensus 12-month target price of $119.35, which represents a ~20.24% return on investment over the next 12 months.
Of the 18 analysts tracking Alexion Pharmaceuticals (ALXN) in August, ~89% of them have recommended a “buy.” Of the 29 analysts tracking Biogen (BIIB) in August, ~69% of them have recommended a “buy.” Of the 23 analysts tracking Vertex Pharmaceuticals (VRTX) in August, ~83% of them have recommended a “buy.”
On August 31, Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Biogen had consensus 12-month target prices of $158.41, $195.52, and $389.20, respectively, which represents a ~29% growth, a ~1.74% decline, and a ~10.34% growth, respectively, over the next 12 months.